HEPATOCELLULAR CARCINOMA (HCC)

This study looked at over 2,600 people with advanced liver cancer that had invaded major blood vessels. Researchers compared standard immunotherapy plus anti-angiogenesis drugs with and without a procedure called TACE (which delivers chemo directly to the liver). The goal was to …

This study tested a new drug, tislelizumab, against the standard treatment sorafenib for adults with advanced liver cancer that cannot be removed by surgery. Over 680 participants were randomly assigned to receive one of the two treatments. The goal was to see which drug worked b…

This study tested whether adding a liver-directed chemotherapy infusion (HAIC) to standard drug therapy (immunotherapy plus anti-angiogenesis drugs) improves survival in people with advanced liver cancer that has spread into the main blood vessel of the liver. Over 1,600 particip…

This study tested whether giving the immunotherapy drug pembrolizumab before and after local ablation (using heat or radiation to destroy tumors) could help shrink liver cancers in 30 patients with early-stage hepatocellular carcinoma. The goal was to see if this approach could m…

This completed study tested whether an artificial intelligence (AI) system can help doctors accurately identify liver tumors from contrast-enhanced CT scans. Over 10,000 adults participated, and the AI's main goal was to correctly tell malignant from non-malignant lesions. The ap…

This study tested whether combining PET/MRI scans with machine learning can more accurately determine how aggressive solid tumors like prostate cancer are. Researchers scanned 50 adults with prostate, liver, kidney, or brain tumors and compared the AI results to standard tissue a…

This study looked at 151 liver cancer patients whose tumors had spread into the bile ducts. Researchers used a special computer model to figure out which patients would benefit most from surgery. The goal was to help doctors make better, personalized decisions to improve long-ter…

This study looked at 1005 liver cancer patients who had surgery to remove their tumors. Researchers used machine learning to figure out which patients would get the most benefit from an additional treatment called transarterial chemoembolization (TACE) after surgery. The goal was…

This study looked back at data from 484 liver cancer patients who had a liver transplant. Researchers wanted to see if taking certain cancer drugs (tyrosine kinase inhibitors) before the transplant helped patients live longer or kept the cancer from coming back. The goal was to f…

This study used artificial intelligence to analyze data from 7,000 people with liver cancer. The goal was to create a tool that helps doctors predict how well a patient might do with different treatments, like surgery or other therapies. The tool is designed to support personaliz…

This study looked at 324 liver cancer patients to see if CT scans could predict who would benefit from a combination of two treatments: a procedure that blocks the tumor's blood supply (TACE) and a targeted drug (TKI). The goal was to find out if certain scan features could help …

This study looked back at medical records of 300 adults with high-risk liver cancer in China. They received a combination of two drugs (atezolizumab and bevacizumab) plus chemotherapy directly into the liver artery. The goal was to see how well this treatment worked and how safe …